Connect to other sites within the UBM Medica Network
Multiple Sclerosis Drug Lemtrada Gets FDA Nod
Approved for patients with relapsing forms of MS, the drug generally should be reserved for those who have had an inadequate response to 2 or more drugs indicated for MS treatment.
What MS Therapies Patients Want
As more treatments become available, patients will have more preferences and will play a more prominent role in directing choices.
MRI Predicts MS Risk, Even Without Symptoms
Determining who is at risk for MS remains difficult, and symptoms may take time to develop even in patients who already have some destroyed myelin. MRI may help.
Multiple Sclerosis Rx: IGF-1?
A new study provides hope for MS treatment with IGF-1, which could ultimately halt the attack of T effector cells on myelin, thereby stopping disease progression.
Vaccines Raise MS Risk Sooner But Not Later
New study findings do not suggest a need for a change in vaccine policy, but even a small increased risk could have an effect on public health.
Acupuncture and MS: The Literature Is Lacking
Studies suggest that acupuncture can improve MS-related symptoms, but poor design makes it difficult to draw robust conclusions.
Age at Onset Predicts Disease Progression in MS
This, the least common MS disease course, carries the worst prognosis. Treatments are urgently needed to prevent or delay the rapid disease progression.
Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.
By clicking Accept, you agree to become a member of the UBM Medica Community.